首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RANTES |
| Uniprot No | P13501 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24 -91aa |
| 氨基酸序列 | SPYSSDTTPC CFAYIARPLP RAHIKEYFYT SGKCSNPAVV FVTRKNRQVC ANPEKKWVRE YINSLEMS |
| 预测分子量 | 10 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于RANTES重组蛋白的参考文献示例(文献标题、作者及摘要概括)：
---
1. **标题**: *"RANTES: a versatile and controversial chemokine"*
**作者**: Appay V, Rowland-Jones SL
**摘要**: 该综述探讨了RANTES作为趋化因子在炎症和HIV感染中的双重作用，重点讨论了重组RANTES蛋白在抑制HIV-1病毒进入靶细胞中的潜在治疗应用。
2. **标题**: *"Recombinant RANTES induces chemotaxis and calcium flux in human eosinophils"*
**作者**: Rot A, Krieger M, Brunner T
**摘要**: 研究利用重组RANTES蛋白验证其对嗜酸性粒细胞的趋化活性，证实其通过结合CCR5受体激活下游信号通路，为哮喘等过敏性疾病机制提供依据。
3. **标题**: *"Production and functional characterization of recombinant RANTES in yeast expression systems"*
**作者**: Ceballos-Alcantarilla E et al.
**摘要**: 报道了在毕赤酵母系统中高效表达重组RANTES的方法，并通过体外实验证明其与天然蛋白相似的趋化活性，为大规模生产提供新策略。
---
注：以上内容为示例性概括，实际文献需通过PubMed/Google Scholar等数据库检索具体信息。建议优先选择近5年高被引论文或权威期刊(如*Nature Immunology*、*Journal of Biological Chemistry*)。
**Background of RANTES Recombinant Protein**
RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted), also known as CCL5. is a member of the CC chemokine family. It is primarily secreted by T lymphocytes, macrophages, endothelial cells, and platelets in response to inflammatory stimuli. RANTES plays a critical role in immune regulation by recruiting leukocytes, such as T cells, eosinophils, and basophils, to sites of inflammation or infection through interactions with its receptors (CCR1. CCR3. and CCR5). This chemotactic activity links RANTES to both physiological immune responses and pathological conditions, including chronic inflammation, autoimmune diseases, and viral infections like HIV.
Recombinant RANTES protein is produced via genetic engineering techniques, often using bacterial, yeast, or mammalian expression systems. The recombinant form retains the native protein’s functional properties, enabling researchers to study its structure, receptor binding, and signaling mechanisms in vitro and in vivo. Its high purity and consistency make it valuable for applications in drug discovery, immunology research, and therapeutic development. For instance, RANTES has been explored as a potential therapeutic target in HIV/AIDS due to its ability to block viral entry by competing for CCR5 co-receptor binding.
Additionally, RANTES is implicated in inflammatory diseases such as rheumatoid arthritis and asthma, where its overexpression correlates with disease severity. However, its dual role in cancer—promoting tumor growth in some contexts while inhibiting metastasis in others—highlights the complexity of its biological functions. Recombinant RANTES thus serves as a vital tool for dissecting these mechanisms and developing targeted therapies. Ongoing research continues to unravel its therapeutic potential and challenges, including balancing beneficial immune modulation with off-target effects.
×
